ExScientia Ltd

Exscientia Plc operates as an AI-driven pharmatech company which is engaged in designing and developing patient-based drugs. The firm has designed three drugs that are in phase 1 human clinical trials. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

ExScientia reports robust Q4 earnings, poised for precision medicine growth

ExScientia's Q4 2022 earnings call highlighted strong financial performance, key collaborations, and advancements in pipeline programs. The company's focus on AI-driven precision medicine and solid cash position bode well for future growth. Challenges in program management and cost control exist, but opportunities for innovation and partnerships are abundant.

ExScientia reports 15% revenue growth, poised for precision medicine leadership

ExScientia Ltd delivered strong financial performance with a 15% increase in quarterly revenue and a robust cash position, driven by successful product launches and cost-saving initiatives.
The company's focus on personalized medicine, innovative product development, and strategic financial management positions it well for future growth and market leadership.
While facing challenges in molecule differentiation and cost efficiency, ExScientia has opportunities to leverage biomarkers, advance clinical programs, and expand market presence.

ExScientia advances clinical trials and precision medicine with strong financials

ExScientia's Q2 2023 earnings call showcased progress in clinical trials, precision medicine, and AI integration, supported by a strong financial position.
The company's focus on innovation, cost efficiency, and strategic partnerships positions them well for future growth and advancements in drug discovery.
Challenges lie in managing milestone payments, operational complexities, and staying competitive through biologics investments and partnerships.
Opportunities abound in expanding collaborations, attracting industry interest, and unveiling advancements in biologics for pipeline growth from 2024 onwards.

ExScientia excels in Q3, poised for growth in precision medicine

ExScientia's Q3 performance reflects progress in oncology programs, financial strength, and a focus on precision drug design and partnerships.
The company's strengths lie in its robust cash position, innovative approach to drug design, and operational efficiency influenced by past projects.
Challenges include market adaptability, program prioritization, and maintaining competitiveness, while opportunities exist in advancing the pipeline and leveraging partnerships for growth.

ExScientia reports robust Q4 earnings, eyes growth through innovation

ExScientia's Q4 2023 earnings call showcases strong financial and operational performance.
The company's focus on innovation, partnerships, and efficiency drives growth.
Challenges include competition, innovation sustainability, and quality maintenance.
Opportunities lie in business development, automation, and efficient drug creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Exscientia Plc engages in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of therapeutic compounds. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom.

OXFORD, England--( BUSINESS WIRE )--Exscientia plc (Nasdaq: EXAI) today announced that EXS4318 ('4318) a compound precision designed by Exscientia and in-licensed by Bristol Myers Squibb in August 2021, has entered Phase 1 clinical trials in the United States. The compound is in development for immunology & inflammation (I&I) indications. Bristol Myers Squibb will oversee the clinical and commercial development and Exscientia is eligible for milestone payments and, if approved, tiered royalties on net product sales.

Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318

VIENNA, Austria & OXFORD, England--( BUSINESS WIRE )--Exscientia plc (Nasdaq: EXAI) today highlighted new data to identify patients that are more likely to respond to its A2A receptor antagonist, EXS-21546 (‘546) as well as the relationship to potential impact of adenosine on PD-1 inhibitor response. The research identified a novel patient selection multi-gene transcript signature, the adenosine burden score (ABS), that will be confirmed in the Company's Phase 1/2 study, IGNITE-AI. The data are being presented at the ESMO Immuno-Oncology Annual Congress, being held December 7-9 in Geneva, Switzerland.

Exscientia Presents Novel Immuno-Oncology Biomarker for EXS-21546 at the ESMO I-O Annual Congress

OXFORD, England--( BUSINESS WIRE )--Exscientia plc (Nasdaq: EXAI) today announced clinical trial application (CTA) approval of IGNITE-AI, enabling site activation in its first European country. IGNITE-AI is a Phase 1/2 trial studying EXS-21546 ('546), Exscientia's A2A receptor antagonist in combination with anti-PD-1 therapy in patients with immunotherapy relapsed or refractory renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC). The study will evaluate safety, efficacy, pharmacokinetics and pharmacodynamics in up to 110 patients. Exscientia intends to expand to additional tumour types, including breast cancer, in future trials after assessment of ‘546 activity and validation of its selection biomarkers.

Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours

Exscientia plc (NASDAQ:EXAI ) Q3 2022 Earnings Conference Call November 15, 2022 8:30 AM ET Company Participants Sara Sherman - Vice President-Investor Relations Andrew Hopkins - Chief Executive Officer & Executive Director Ben Taylor - Chief Financial Officer & Chief Strategy Officer Dave Hallett - Chief Operating Officer Mike Krams - Chief Quantitative Medicine Officer Garry Pairaudeau - Chief Technology Officer Conference Call Participants Michael Ryskin - Bank of America Operator Hello, everyone. My name is Brent and I will be your conference operator today.

Exscientia plc (EXAI) Q3 2022 Earnings Call Transcript

Exscientia PLC Sponsored ADR (EXAI) delivered earnings and revenue surprises of -72.73% and 47.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Exscientia PLC Sponsored ADR (EXAI) Reports Q3 Loss, Lags Revenue Estimates

OXFORD, U.K.--( BUSINESS WIRE )--Exscientia plc (Nasdaq: EXAI)

Exscientia Business and Financial Update for the Third Quarter 2022

OXFORD, England & HOUSTON, Texas--( BUSINESS WIRE )--Exscientia plc (Nasdaq: EXAI) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to align the patient-centric artificial intelligence (AI) capabilities of Exscientia with the drug discovery and development expertise of MD Anderson in order to advance novel small-molecule oncology therapies.

Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) will report financial results for the third quarter ended September 30, 2022, on Tuesday, November 15, 2022, before the open of U.S. markets.

Exscientia to Report Third Quarter 2022 Financial Results on November 15, 2022

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced the expansion of its platform to include the design of biologics, such as human antibodies.

Exscientia Expands Biologics Design Capability with Automated Laboratory

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in November: BofA Securities 2022 A.I.

Exscientia to Present at Upcoming Investor Conferences in November

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) is honoured to announce that the company has won the Prix Galien USA 2022 Award for Best Digital Health Solution in recognition of its AI-driven precision medicine platform.

Exscientia Wins Prix Galien USA 2022 Digital Health Solution Award

VIENNA, Austria & OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today highlighted new data aimed at enriching for patients that are more likely to respond to its precision-designed CDK7 inhibitor, GTAEXS-617 (‘617).

Exscientia Presents Novel Patient Stratification and Biomarker Data for GTAEXS-617 at the 34th EORTC-NCI-AACR Annual Symposium

VIENNA & OXFORD, England--(BUSINESS WIRE)--Exscientia (Nasdaq: EXAI), ETH Zurich, the Medical University of Vienna, and the Center for Molecular Medicine (CeMM) today announced a new publication in Blood Cancer Discovery, a journal of the American Association for Cancer Research, titled “Deep Morphology Learning Enhances Precision Medicine by Image-Based Ex Vivo Drug Testing” from the laboratory of Prof. Berend Snijder. This post-hoc analysis builds on the transformative work of the EXALT-1 tri

Blood Cancer Discovery Publication Further Validates Exscientia's AI Precision Medicine Platform for Improving Patient Outcomes

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced that Caroline Rowland has joined Exscientia as Chief People Officer. In this newly created role, she will lead Exscientia's People (human resources) and Places functions and build on the Company's talent, training and employee experience strategies. Caroline reports to CEO and Founder, Andrew Hopkins, DPhil. “Exscientia was founded to create an entirely new type of biopharma company, re-engineered to integrate techn

Exscientia Welcomes Caroline Rowland as Chief People Officer

Exscientia plc (NASDAQ:EXAI ) Q2 2022 Earnings Conference Call August 18, 2022 8:30 AM ET Company Participants Sara Sherman - VP, IR Andrew L. Hopkins - Founder and CEO Ben R.

Exscientia plc (EXAI) CEO Andrew Hopkins on Q2 2022 Results - Earnings Call Transcript

Frontier IP has sold a further 391,200 ADS in investee company Exscientia at an average price of US$11.97 raising net proceeds of approximately US$4.68mln. Since January, net proceeds from sales of Exscientia shares amount to approximately £9.96mln, said Frontier IP, generating an estimated realised gain of £2.79mln in the financial year to 30 June 2022 and £0.31mln in the financial year to 30 June 2023.

Frontier IP further trims stake in Exscientia

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) Recent developments in the Company's pipeline, collaborations, and operations, as well as financial results for the second quarter and first half 2022, are summarised below. In addition, Exscientia will host a conference call Thursday, August 18 at 1:30 p.m. BST / 8:30 a.m. ET to provide an overview of the company's pipeline and corporate strategy. “In the first half of 2022, we delivered on major new and existing collaborations, a

Exscientia Business Update for Second Quarter and First Half 2022

OXFORD, England--(BUSINESS WIRE)--Exscientia (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, will report financial results for the second quarter ended June 30, 2022, on Wednesday, August 17, 2022 after U.S. market close. Following the announcement, the Company will host a conference call and webcast at 1:30 p.m. BST / 8:30 a.m. ET on Thursday, August 18, 2022, to provide an over

Exscientia to Report Second Quarter 2022 Financial Results on August 17, 2022

The average of price targets set by Wall Street analysts indicates a potential upside of 62.6% in Exscientia PLC Sponsored ADR (EXAI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Exscientia PLC Sponsored ADR (EXAI) Could Surge 63%: Read This Before Placing a Bet

Evotec SE

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced data from its Phase 1 healthy volunteer study of EXS-21546, its highly selective A2A receptor antagonist co-invented and developed through a collaboration between Exscientia and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; Nasdaq: EVO). Topline data from this healthy volunteer study confirmed Exscientia's target product profile design, including potency, high receptor selectivity and ex

Exscientia Reports Topline Data From EXS-21546 Phase 1a Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy Volunteers

OXFORD, England--(BUSINESS WIRE)--Exscientia (Nasdaq: EXAI) today announced that Andrew Hopkins, DPhil., Exscientia's founder and CEO, and Dave Hallett, Chief Operations Officer, will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022 at 9:20 a.m. P.T. (5:20 p.m. BST). A live webcast of the fireside chat will be available on the Company's website, under the “Investors & Media” section at www.investors.exscientia.ai. An arch

Exscientia to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

Exscientia PLC Sponsored ADR (EXAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Exscientia PLC Sponsored ADR (EXAI) Upgraded to Buy: Here's Why

Exscientia plc (NASDAQ:EXAI ) Q1 2022 Earnings Conference Call May 26, 2022 8:30 AM ET Company Participants Sara Sherman - Vice President of Investor Relations Andrew Hopkins - Chief Executive Officer Nikolaus Krall - Vice President of Precision Medicine Ben Taylor - Chief Financial Officer and Chief Strategy Officer Dave Hallett - Chief Operations Officer Conference Call Participants Chris Shibutani - Goldman Sachs Group, Inc. Peter Lawson - Barclays Bank PLC Vikram Purohit - Morgan Stanley Michael Ryskin - Bank of America Merrill Lynch Christopher Zopf - Goldman Sachs Operator Hello, everyone. My name is Brent, and I will be your conference operator today.

Exscientia plc (EXAI) CEO Andrew Hopkins on Q1 2022 Results - Earnings Call Transcript

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) Recent advancements in the Company's pipeline, collaborations, and operations, as well as financial results for the first quarter 2022, are summarised below. In addition, Exscientia will host a conference call Thursday, May 26 at 1:30 p.m. BST / 8:30 a.m. ET to provide an overview of the Company's precision medicine platform. "We started 2022 by commencing a groundbreaking collaboration with Sanofi to develop a pipeline of AI-desig

Exscientia Business Update for First Quarter 2022

OXFORD, England--(BUSINESS WIRE)--Exscientia (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, will report financial results for the first quarter ended March 31, 2022, on Wednesday, May 25, 2022 after U.S. market close. Following the announcement, the Company will host a conference call and webcast at 1:30 p.m. BST / 8:30 a.m. ET on Thursday, May 26, 2022, to provide an overview o

News for ExScientia Ltd Stock (EXAI)